503 related articles for article (PubMed ID: 16105565)
21. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Ge Y; Biek D; Talbot GH; Sahm DF
Antimicrob Agents Chemother; 2008 Sep; 52(9):3398-407. PubMed ID: 18625769
[TBL] [Abstract][Full Text] [Related]
22. Bacterial ventriculoperitoneal shunt infections: changing trends in antimicrobial susceptibility, a 7-year retrospective study from Pakistan.
Akram Asif A; Mahmood K; Riaz S; McHugh T; Sultan S
Antimicrob Resist Infect Control; 2023 Aug; 12(1):75. PubMed ID: 37553715
[TBL] [Abstract][Full Text] [Related]
23. Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens.
Salpadoru T; Pinks KE; Lieberman JA; Cotton K; Wozniak KL; Gerasimchuk N; Patrauchan MA
Microbiol Spectr; 2024 Jun; 12(6):e0423423. PubMed ID: 38651882
[TBL] [Abstract][Full Text] [Related]
24. Bacterial contamination in intensive care unit at Al-Imam Al-Hussein Hospital in Thi-qar province in Iraq.
Nasser NE; Abbas AT; Hamed SL
Glob J Health Sci; 2012 Nov; 5(1):143-9. PubMed ID: 23283046
[TBL] [Abstract][Full Text] [Related]
25. Microbial evaluation and public health implications of urine as alternative therapy in clinical pediatric cases: health implication of urine therapy.
Ogunshe AA; Fawole AO; Ajayi VA
Pan Afr Med J; 2010 May; 5():12. PubMed ID: 21293739
[TBL] [Abstract][Full Text] [Related]
26. Nosocomial Infections: Multicenter surveillance of antimicrobial resistance profile of Staphylococcus aureus and Gram negative rods isolated from blood and other sterile body fluids in Iran.
Poorabbas B; Mardaneh J; Rezaei Z; Kalani M; Pouladfar G; Alami MH; Soltani J; Shamsi-Zadeh A; Abdoli-Oskooi S; Saffar MJ; Alborzi A
Iran J Microbiol; 2015 Jun; 7(3):127-35. PubMed ID: 26668699
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007).
Kresken M; Leitner E; Seifert H; Peters G; von Eiff C
Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):1007-11. PubMed ID: 19296137
[TBL] [Abstract][Full Text] [Related]
28. Incidence, pathogens and antimicrobial resistance of blood and cerebrospinal fluid isolates from a tertiary neonatal unit in South Africa: A 10 year retrospective review.
Thomas R; Ondongo-Ezhet C; Motsoaledi N; Sharland M; Clements M; Velaphi S
PLoS One; 2024; 19(1):e0297371. PubMed ID: 38241304
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis.
Tunney MM; Elborn JS; McLaughlin CS; Longshaw CM
J Glob Antimicrob Resist; 2024 Mar; 36():407-410. PubMed ID: 38336228
[TBL] [Abstract][Full Text] [Related]
30. In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Biedenbach DJ; Huband MD; Hackel M; de Jonge BL; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2015 Oct; 59(10):6053-63. PubMed ID: 26195518
[TBL] [Abstract][Full Text] [Related]
31. A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012.
Cattoir V; Dowzicky MJ
Antimicrob Resist Infect Control; 2014; 3(1):36. PubMed ID: 25671097
[TBL] [Abstract][Full Text] [Related]
32. Reservoirs of Nosocomial Pathogens in Intensive Care Units: A Systematic Review.
Osman AH; Darkwah S; Kotey FCN; Odoom A; Hotor P; Dayie NTKD; Donkor ES
Environ Health Insights; 2024; 18():11786302241243239. PubMed ID: 38828046
[TBL] [Abstract][Full Text] [Related]
33. Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002).
Jones ME; Draghi DC; Thornsberry C; Karlowsky JA; Sahm DF; Wenzel RP
Ann Clin Microbiol Antimicrob; 2004 Jul; 3():14. PubMed ID: 15283864
[TBL] [Abstract][Full Text] [Related]
34. Changing patterns of bacterial profile and antimicrobial resistance in high-risk patients during the COVID-19 pandemic at a tertiary oncology hospital.
Abdel-Hamid RM; El-Mahallawy HA; Allam RM; Zafer MM; Elswify M
Arch Microbiol; 2024 May; 206(6):250. PubMed ID: 38722362
[TBL] [Abstract][Full Text] [Related]
35. Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.
El Chakhtoura NG; Saade E; Iovleva A; Yasmin M; Wilson B; Perez F; Bonomo RA
Expert Rev Anti Infect Ther; 2018 Feb; 16(2):89-110. PubMed ID: 29310479
[TBL] [Abstract][Full Text] [Related]
36. Current trends in antimicrobial resistance of ESKAPEEc pathogens from bloodstream infections - Experience of a tertiary care centre in North India.
Gupta M; Gupta V; Gupta R; Chaudhary J
Indian J Med Microbiol; 2024 Jun; 50():100647. PubMed ID: 38871082
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial Resistance Patterns in Patients with Vaginal Discharge: A 2019-2022 Analysis at the National Health Laboratory in Eritrea.
Hussein K; Tesfai B; Frezgi O; Hayelom H; Gebremeskel Y; Werede A; Gebremariam H; Kibreab F; Hamida ME
Biomed Res Int; 2024; 2024():7193490. PubMed ID: 38577704
[TBL] [Abstract][Full Text] [Related]
38. The importance of the bacterial spectrum in the clinical diagnostics and management of patients with spontaneous pyogenic spondylodiscitis and isolated spinal epidural empyema: a 20-year cohort study at a single spine center.
Hijazi MM; Siepmann T; El-Battrawy I; Schröttner P; Podlesek D; Schackert G; Juratli TA; Eyüpoglu IY; Filis A
BMC Infect Dis; 2024 Jan; 24(1):39. PubMed ID: 38166791
[TBL] [Abstract][Full Text] [Related]
39. Distribution and Drug Resistance of Common Pathogens Causing Lower Respiratory Tract Infection in Xinjiang Region.
Wang L; Guo H; Qu L; Wang G; Luo J
Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38430170
[TBL] [Abstract][Full Text] [Related]
40. In Vitro and In Vivo Control of Secondary Bacterial Infection Caused by Leishmania major.
Yehia HM; Al-Olayan EM; El-Khadragy MF; Metwally DM
Int J Environ Res Public Health; 2017 Jul; 14(7):. PubMed ID: 28703780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
